These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 39175074)
1. Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer. Fan X; Qi A; Zhang M; Jia Y; Li S; Han D; Liu Y Diagn Pathol; 2024 Aug; 19(1):113. PubMed ID: 39175074 [TBL] [Abstract][Full Text] [Related]
2. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer. Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497 [TBL] [Abstract][Full Text] [Related]
3. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer. Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441 [TBL] [Abstract][Full Text] [Related]
4. SOX13 is a novel prognostic biomarker and associates with immune infiltration in breast cancer. Gao T; Jiang B; Zhou Y; He R; Xie L; Li Y Front Immunol; 2024; 15():1369892. PubMed ID: 38707897 [TBL] [Abstract][Full Text] [Related]
5. Anoikis-related genes in breast cancer patients: reliable biomarker of prognosis. Tang M; Rong Y; Li X; Pan H; Tao P; Wu Z; Liu S; Tang R; Liu Z; Cai H BMC Cancer; 2024 Sep; 24(1):1163. PubMed ID: 39300389 [TBL] [Abstract][Full Text] [Related]
6. Identifying subtypes and developing prognostic models based on N6-methyladenosine and immune microenvironment related genes in breast cancer. Wang L; Li J; Mei N; Chen H; Niu L; He J; Wang R Sci Rep; 2024 Jul; 14(1):16586. PubMed ID: 39020010 [TBL] [Abstract][Full Text] [Related]
7. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321 [No Abstract] [Full Text] [Related]
8. CYB561 is a potential therapeutic target for breast cancer and is associated with immune cell infiltration. Zhuo J; Zhao Y; Hao R; Li H; Zheng Z; Dai L; Sheng A; Yao H; Tang Y; Wang R; Yang X; Liu W Eur J Med Res; 2024 Aug; 29(1):414. PubMed ID: 39135107 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
10. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA. Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905 [No Abstract] [Full Text] [Related]
11. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study. Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821 [TBL] [Abstract][Full Text] [Related]
12. Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients. Mu G; Ji H; He H; Wang H Breast Cancer; 2021 Mar; 28(2):513-526. PubMed ID: 33245478 [TBL] [Abstract][Full Text] [Related]
13. Claudin expression in breast cancer: high or low, what to expect? Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of vesicle-associated membrane protein 7 in breast cancer tissues. Huang Y; Wu M; Li JD; Qin Z; Huang KQ; Cui JZ; Ou HL Technol Health Care; 2024; 32(4):2141-2157. PubMed ID: 38393934 [TBL] [Abstract][Full Text] [Related]
15. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates. Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567 [TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer. Wang Z; Liu H; Gong Y; Cheng Y Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948 [TBL] [Abstract][Full Text] [Related]
17. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer. Tang W; Xu F; Zhao M; Zhang S BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817 [TBL] [Abstract][Full Text] [Related]
18. A novel immune-related prognostic index for predicting breast cancer overall survival. Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Prognostic Relevance of Differential Claudin Gene Expression Highlights Claudin-4 as Being Suppressed by TGFβ1 Inhibitor in Colorectal Cancer. Yang L; Zhang W; Li M; Dam J; Huang K; Wang Y; Qiu Z; Sun T; Chen P; Zhang Z; Zhang W Front Genet; 2022; 13():783016. PubMed ID: 35281827 [No Abstract] [Full Text] [Related]
20. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]